Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Natera’s genomic jargon isn’t easy. Each 10-K details everything from cfDNA assay accuracy to payer reimbursement disputes, while 8-K updates often cover fast-moving clinical-trial milestones. If you’ve ever wondered how to locate test-volume data, or needed Natera insider trading Form 4 transactions before the market reacts, you know the challenge.
Stock Titan solves it. Our AI reads every Natera quarterly earnings report 10-Q filing, highlights revenue per test, and translates accounting footnotes into plain language. Real-time alerts flag Natera Form 4 insider transactions real-time, so you can track executive stock moves the moment they hit EDGAR. Need the full picture? We link each 10-K, 10-Q, 8-K, proxy DEF 14A, and S-8 in one place—Natera SEC filings explained simply. Common questions such as “How do I find the latest Natera proxy statement executive compensation?” or “Where is the Natera 8-K material events explained?” are answered inside every filing card.
Our platform doesn’t stop at document delivery. AI-powered summaries spotlight what matters for a diagnostics company: R&D spend versus cash on hand, progress of the Signatera oncology pipeline, and changes in CMS reimbursement that can swing margins. Use cases include:
- Compare quarter-over-quarter test volumes without sifting through tables
- Monitor Natera executive stock transactions Form 4 for buying or selling trends
- Assess dilution risk by reviewing shelf registrations and ATM offerings
- Download an Natera annual report 10-K simplified PDF automatically annotated by AI
- Receive instant alerts when a new Natera earnings report filing analysis is available
- Get guidance on understanding Natera SEC documents with AI-generated glossaries
Whether you’re a healthcare analyst, portfolio manager, or clinician-investor, Stock Titan turns Natera’s dense disclosures into actionable insight—no genetics PhD required.
Natera (NTRA) co‑founder and director reported open‑market sales of common stock made under Rule 10b5‑1 trading plans. On 10/15/2025, sales of 153, 1,506, 988, and 423 shares executed at weighted average prices of
On 10/17/2025, trusts sold 475, 275, 413, and 337 shares at weighted average prices of
Insider filing summary: Natera, Inc. director and Secretary & Chief Legal Officer Daniel Rabinowitz had 2,500 restricted stock units (RSUs) vest on 09/29/2025, each representing one share. Those RSUs converted into 2,500 shares of common stock. On 09/30/2025 the reporting person sold 1,364 shares at $162.0528 per share to satisfy tax withholding obligations tied to the RSU vesting, leaving the reporting person with 203,300 shares beneficially owned after the transactions. The sale was made pursuant to written instructions intended to meet Rule 10b5-1(c) affirmative defense conditions.
Michael Brophy, Chief Financial Officer of Natera, Inc. (NTRA), reported vesting and a subsequent sale of shares tied to restricted stock units. On 09/29/2025 6,250 RSUs vested from a 25,000-share grant originally issued on 01/22/2021, where each RSU converts to one share. The reporting shows an immediate beneficial ownership increase to 71,680 shares, followed by a sale on 09/30/2025 of 2,491 shares at $162.0528 per share to satisfy tax withholding, leaving 69,189 shares beneficially owned. The sale was carried out under a written instruction intended to meet Rule 10b5-1(c) conditions. The Form 4 was signed by an attorney-in-fact on 10/01/2025.
Form 144 filing for Natera, Inc. (NTRA) reporting a proposed sale of 14,083 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $2,253,232.54. The shares represent restricted stock acquired from the issuer on 09/28/2025 and the filer indicates the approximate date of sale as 10/01/2025 on NASDAQ. The filing lists five prior sales by the same person during the past three months totaling 23,943 shares with gross proceeds shown for each sale. The notice includes the standard attestation that the seller does not possess undisclosed material adverse information.
Form 144 notice for NTRA: An individual proposes to sell 3,000 shares of Natera common stock through Morgan Stanley Smith Barney LLC with an indicated aggregate market value of $479,968.80 and an approximate sale date of 10/01/2025. The shares to be sold were acquired as restricted stock from the issuer in January 2025 (833 and 2,167 shares on 01/27/2025 and 01/26/2025 respectively). The filing also lists multiple prior open-market sales by the same seller totaling 12,372 shares across July–September 2025 with published gross proceeds on each transaction. The filer attests no undisclosed material adverse information and follows Rule 144 disclosure requirements.
Insider sales by a Natera director under pre-established plans — Sheena Jonathan, a director and co-founder of Natera, reported multiple sales of NTRA common stock executed under Rule 10b5-1 trading plans. On 09/17/2025 she sold 2,814 shares at a weighted average of $175.8835 and 256 shares at $176.6094, leaving 239,182 shares directly owned. On 09/19/2025 additional sales were reported including 3,444 shares and several smaller lots sold on behalf of two trusts, with reported weighted average prices in the $178.51 to $180.69 ranges. The filings state the trust-held shares are disclaimed as beneficial ownership by the reporting person.
Natera, Inc. (NTRA) insider Matthew Rabinowitz reported sales totaling 50,000 shares of common stock on September 18-19, 2025. The dispositions were effected under two separate Rule 10b5-1 trading plans adopted on June 13, 2025 and March 14, 2025, with reported weighted-average prices in ranges around $180.00–$181.40 per share. After these transactions the reporting person directly beneficially owned 2,320,852 shares and indirectly beneficially owned 15,000 shares through a spouse. No derivative securities were reported. The Form 4 was signed by an attorney-in-fact on September 19, 2025.
Natera, Inc. (NTRA) Form 144 notice reports a proposed sale of 25,527 common shares valued at $4,591,286.22 to be sold on 09/19/2025 on NASDAQ through Morgan Stanley Smith Barney LLC. The shares were acquired on 08/08/2024 through previously exercised stock options and paid in cash. The filer discloses multiple recent sales over the past three months, including 10b5-1 program sales: 14,473 shares by Matthew Rabinowitz on 09/18/2025 (gross proceeds $2,607,069.25) and several sales by related trust entities totaling 31,718 shares with combined proceeds reported. The filer certifies no undisclosed material adverse information and notes reliance on Rule 10b5-1 sales where indicated.
Natera, Inc. insider sale notice for common stock. The filer reports a proposed sale of 22,000 common shares through Charles Schwab & Co., with an aggregate market value of $4,237,900 and approximately 137,248,106 shares outstanding, representing about 0.016% of outstanding stock. The shares were originally acquired as founders' shares on 04/30/2012 from the issuer. The form also discloses five prior sales by the same person in July–September 2025 totaling 15,210 shares and gross proceeds shown for each trade. The filer attests no undisclosed material adverse information and includes standard Rule 144 representations.
Natera, Inc. (NTRA) notice reports a proposed sale of 10,000 common shares through Morgan Stanley Smith Barney with an aggregate market value of $1,800,000. The filing lists 137,248,106 shares outstanding, so the block represents about 0.0073% of outstanding stock, indicating a very small ownership fraction being sold. The shares were acquired as a gift on 03/02/2020 from the issuer, and the filing discloses two recent sales in the past three months: 5,000 shares sold on 09/12/2025 for $852,707 and 1,718 shares sold on 07/28/2025 for $240,190.65. The filer certifies they are not aware of any undisclosed material adverse information.
FAQ
What is the current stock price of Natera (NTRA)?
What is the market cap of Natera (NTRA)?
